Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Key Points

• This research aims to evaluate the efficacy and safety of oxymetazoline hydrochloride 0.1% in treating blepharoptosis.
• Phase 3 clinical trial design
• Comparison of oxymetazoline 0.1% treatment to placebo
• Duration of treatment assessed over six months
• Measurement of MRD-1 as a primary outcome
• Significant increase in MRD-1 after 14 days of oxymetazoline treatment compared to placebo
• No loss of effect observed after six months of treatment
• No significant safety concerns reported during the study